85 related articles for article (PubMed ID: 1620704)
1. DNA adducts induced by platinum drug chemotherapeutic agents in human tissues.
Poirier MC; Shamkhani H; Reed E; Tarone RE; Gupta-Burt S
Prog Clin Biol Res; 1992; 374():197-212. PubMed ID: 1620704
[No Abstract] [Full Text] [Related]
2. Persistence of platinum-ammine-DNA adducts in gonads and kidneys of rats and multiple tissues from cancer patients.
Poirier MC; Reed E; Litterst CL; Katz D; Gupta-Burt S
Cancer Res; 1992 Jan; 52(1):149-53. PubMed ID: 1727376
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of cis-diamminedichloroplatinum II (cisplatin)-DNA-intrastrand adducts in testicular and ovarian cancer patients receiving cisplatin chemotherapy.
Reed E; Yuspa SH; Zwelling LA; Ozols RF; Poirier MC
J Clin Invest; 1986 Feb; 77(2):545-50. PubMed ID: 3944268
[TBL] [Abstract][Full Text] [Related]
4. Relationship between patient response in ovarian and breast cancer and platinum drug-DNA adduct formation.
Gupta-Burt S; Shamkhani H; Reed E; Tarone RE; Allegra CJ; Pai LH; Poirier MC
Cancer Epidemiol Biomarkers Prev; 1993; 2(3):229-34. PubMed ID: 8318875
[TBL] [Abstract][Full Text] [Related]
5. cis-Diamminedichloroplatinum (II)-DNA adduct formation in renal, gonadal, and tumor tissues of male and female rats.
Reed E; Litterst CL; Thill CC; Yuspa SH; Poirier MC
Cancer Res; 1987 Feb; 47(3):718-22. PubMed ID: 3802077
[TBL] [Abstract][Full Text] [Related]
6. Kinetics of the formation and removal of cisplatin-DNA adducts in blood cells and tumor tissue of cancer patients receiving chemotherapy: comparison with in vitro adduct formation.
Fichtinger-Schepman AM; van der Velde-Visser SD; van Dijk-Knijnenburg HC; van Oosterom AT; Baan RA; Berends F
Cancer Res; 1990 Dec; 50(24):7887-94. PubMed ID: 2253228
[TBL] [Abstract][Full Text] [Related]
7. Relationship between platinum-DNA adducts in leukocytes of patients with advanced germ cell cancer and survival.
Fisch MJ; Howard KL; Einhorn LH; Sledge GW
Clin Cancer Res; 1996 Jun; 2(6):1063-6. PubMed ID: 9816268
[TBL] [Abstract][Full Text] [Related]
8. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Pietras RJ; Pegram MD; Finn RS; Maneval DA; Slamon DJ
Oncogene; 1998 Oct; 17(17):2235-49. PubMed ID: 9811454
[TBL] [Abstract][Full Text] [Related]
9. DNA adducts in human and patas monkey maternal and fetal tissues induced by platinum drug chemotherapy.
Shamkhani H; Anderson LM; Henderson CE; Moskal TJ; Runowicz CD; Dove LF; Jones AB; Chaney SG; Rice JM; Poirier MC
Reprod Toxicol; 1994; 8(3):207-16. PubMed ID: 8075509
[TBL] [Abstract][Full Text] [Related]
10. Platinum drug-DNA interactions in human tissues measured by cisplatin-DNA enzyme-linked immunosorbent assay and atomic absorbance spectroscopy.
Poirier MC; Reed E; Shamkhani H; Tarone RE; Gupta-Burt S
Environ Health Perspect; 1993 Mar; 99():149-54. PubMed ID: 8319613
[TBL] [Abstract][Full Text] [Related]
11. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines.
Mamenta EL; Poma EE; Kaufmann WK; Delmastro DA; Grady HL; Chaney SG
Cancer Res; 1994 Jul; 54(13):3500-5. PubMed ID: 8012973
[TBL] [Abstract][Full Text] [Related]
12. Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation.
Evans DL; Tilby M; Dive C
Cancer Res; 1994 Mar; 54(6):1596-603. PubMed ID: 8137265
[TBL] [Abstract][Full Text] [Related]
13. Determination of carcinogen-DNA adducts by immunoassay.
Poirier MC; Liou SH; Reed E; Strickland PT; Tockman MS
J UOEH; 1989 Mar; 11 Suppl():353-67. PubMed ID: 2664949
[No Abstract] [Full Text] [Related]
14. Inductively coupled plasma mass spectroscopy quantitation of platinum-DNA adducts in peripheral blood leukocytes of patients receiving cisplatin- or carboplatin-based chemotherapy.
Bonetti A; Apostoli P; Zaninelli M; Pavanel F; Colombatti M; Cetto GL; Franceschi T; Sperotto L; Leone R
Clin Cancer Res; 1996 Nov; 2(11):1829-35. PubMed ID: 9816137
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of platinum-DNA adduct levels relative to known prognostic variables in a cohort of ovarian cancer patients.
Reed E; Ostchega Y; Steinberg SM; Yuspa SH; Young RC; Ozols RF; Poirier MC
Cancer Res; 1990 Apr; 50(8):2256-60. PubMed ID: 2180564
[TBL] [Abstract][Full Text] [Related]
16. [A new cytostatic agent: cis-dischlorodiamin platinum II (DDP)].
Gallmeier WM; Bruntsch U
MMW Munch Med Wochenschr; 1979 May; 121(18):624-7. PubMed ID: 108586
[No Abstract] [Full Text] [Related]
17. Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian carcinoma cell lines in vitro.
Shellard SA; Hosking LK; Hill BT
Cancer Res; 1991 Sep; 51(17):4557-64. PubMed ID: 1873800
[TBL] [Abstract][Full Text] [Related]
18. Cis-platinum in the treatment of testicular and other cancers.
Williams SD; Einhorn LH
Adv Intern Med; 1982; 27():531-45. PubMed ID: 7041553
[No Abstract] [Full Text] [Related]
19. Platinum concentrations and DNA adduct levels in tumors and organs of cisplatin-treated LOU/M rats inoculated with cisplatin-sensitive or -resistant immunoglobulin M immunocytoma.
Fichtinger-Schepman AM; Vendrik CP; van Dijk-Knijnenburg WC; de Jong WH; van der Minnen AC; Claessen AM; van der Velde-Visser SD; de Groot G; Wubs KL; Steerenberg PA
Cancer Res; 1989 Jun; 49(11):2862-7. PubMed ID: 2720647
[TBL] [Abstract][Full Text] [Related]
20. [Prospects for using platinum coordination compounds possessing antitumor activity].
Sidorik EP; Burlaka AP; Sirdorik OA; Korchevaia LM
Eksp Onkol; 1984; 6(6):6-12. PubMed ID: 6396067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
